OOIR: Observatory of International Research

Papers

(The TQCC of Annals of Hematology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Blood type and outcomes in patients with COVID-19	226
COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry	122
Hematological findings in coronavirus disease 2019: indications of progression of disease	117
Signals of Th2 immune response from COVID-19 patients requiring intensive care	100
COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure	85
Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry	65
Clozapine-induced agranulocytosis	64
Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience	56
Central venous catheter–related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German S	56
Hematologic disorders associated with COVID-19: a review	55
Characteristics of coagulation alteration in patients with COVID-19	52
Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies	51
Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies	51
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes	47
Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19	47
COVID-19 infection associated with autoimmune hemolytic anemia	44
Impact of rituximab on COVID-19 outcomes	43
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working	39
Hematologic changes predict clinical outcome in recovered patients with COVID-19	37
Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection	37
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the Ge	35
Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma	34
Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy	34
Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infect	34
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes	33

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies	31
Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma	29
Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia	29
Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data	29
Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?	28
De-escalation of empiric broad spectrum antibiotics in hematopoietic stem cell transplant recipients with febrile neutropenia	27
Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis	27
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial	26
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation	26
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life	26
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes	25
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century	25
Hemolytic anemia in COVID-19	25
Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for	25
Concise review: how do red blood cells born, live, and die?	25
Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation	24
Outcomes of Richter’s transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database	24
A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study	23
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort	23
ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies	22
Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review	21
Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study	21
Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125	21
Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis	21
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US	21
Morbidity-free survival and hemoglobin level in non-transfusion-dependent β-thalassemia: a 10-year cohort study	21
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval	21
SARS-CoV-2-associated cold agglutinin disease: a report of two cases	20
Variations in hemoglobin level and morbidity burden in non-transfusion-dependent β-thalassemia	20
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-ce	20
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey	20
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine	20
Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial	19
Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies	19
COVID-19 pandemic and transfusion medicine: the worldwide challenge and its implications	19
Castleman disease and TAFRO syndrome	18
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis	18
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience	18
G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?	18
Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials	18
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives	18
Risk factors for monoclonal gammopathy of undetermined significance: a systematic review	18
Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting	18
Fatal SARS-CoV-2 coinfection in course of EBV-associated lymphoproliferative disease	17
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A	17
Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis	17
A study of the geographic distribution and associated risk factors of leg ulcers within an international cohort of sickle cell disease patients: the CASiRe group analysis	17
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP)	17
Functional polymorphisms of BCL11A and HBS1L-MYB genes affect both fetal hemoglobin level and clinical outcomes in a cohort of children with sickle cell anemia	16
Supportive and palliative care in hemato-oncology: how best to achieve seamless integration and subspecialty development?	16

Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation	16
Skin changes in hairy cell leukemia	16
Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells—single-center experience	16
The emerging therapeutic landscape of relapsed/refractory multiple myeloma	16
An eleven-year cohort of bloodstream infections in 552 febrile neutropenic patients: resistance profiles of Gram-negative bacteria as a predictor of mortality	16
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study	16
Comparison of the clinical course of COVID-19 infection in sickle cell disease patients with healthcare professionals	15
Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab	15
Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia	15
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia	15
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data	15
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice—data from a Belgian registry	15
Daratumumab for refractory warm autoimmune hemolytic anemia	15
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms	15
Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia	15
Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients	14
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib	14
Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arab	14
Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophos	14
Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia	14
Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017)	14
Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies	14
Acute lymphoblastic leukemia–like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients	14
Modern management of splenomegaly in patients with myelofibrosis	14
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report	14
Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major	14
Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma	14
Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic	14
Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse ris	14
Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes—results of a retrospective analysis from a German university	13
Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome	13
Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue	13
SARS-CoV-2 infection in children with febrile neutropenia	13
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial	13
Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation	13
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis	13
Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa	13
Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia	13
Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection	13
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study	13
Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen	13
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia	13
Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis	12
Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma	12
Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review	12
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria	12
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience	12
Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia	12
Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation	12
Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status	12
KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients	12
Tissue factor–bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study	12
Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients	11
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies	11
COVID-19 presenting as neutropenic fever	11
Extracellular vesicles from thalassemia patients carry iron-containing ferritin and hemichrome that promote cardiac cell proliferation	11
Risk and impact of invasive fungal infections in patients with multiple myeloma	11
Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis	11
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma	11
Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy—a case report	11
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials	11
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience	11
Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience	11
Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies	11
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma	11
Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma	11
Clinical association between thyroid disease and immune thrombocytopenia	11
Reduced-intensity, risk factor–stratified immunosuppression for acquired hemophilia A: single-center observational study	11
dsDNA from extracellular vesicles (EVs) in adult AML	11
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma	11
Thrombocytosis in children and adolescents—classification, diagnostic approach, and clinical management	11
Detection of the MYD88L265P and CXCR4S338X mutations by cell-free DNA in Waldenström macroglobulinemia	11
Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)	11
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?	11
Deep venous thrombosis and pulmonary embolism after COVID-19 mRNA vaccination	10
L-glutamine for sickle cell disease: more than reducing redox	10
Amyloidosis and COVID-19: experience from an amyloid program in Canada	10
High density of IgG4-secreting plasma cells in the fibrotic tissue from a surgically resected tracheal ring impaired by complex subglottic stenosis post-tracheostomy as immune expression of a Th2 resp	10
Phase II study of single-agent nivolumab in patients with myelofibrosis	10
Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation	10

Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center	10
Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis	10
Coombs-negative hemolytic anemia and elevated plasma hemoglobin levels in COVID-19	10
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies	10
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of	10
High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease	10
Long non-coding RNA CCAT2 as a potential serum biomarker for diagnosis and prognosis of multiple myeloma	10
Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study	10
Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis	10
Favorable outcome of SARS-CoV-2 infection in pediatric hematology oncology patients during the second and third pandemic waves in Italy: a multicenter analysis from the Infectious Diseases Working Gro	10
UNC0638 induces high levels of fetal hemoglobin expression in β-thalassemia/HbE erythroid progenitor cells	10
Krüppel-like factor 1 (KLF1) gene single nucleotide polymorphisms in sickle cell disease and its association with disease-related morbidities	10
Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries	10
Reevaluation of reference values for bone marrow differential counts in 236 healthy bone marrow donors	10
Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era	9
Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells	9
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes	9
The FLAMSA concept—past and future	9
Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma	9
Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting	9
COVID-19, impact on myeloma patients	9
Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin	9
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kina	9
Prognostic value of 25-hydroxy vitamin D in extranodal NK/T cell lymphoma	9
Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study	9
Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives	9
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma	9
Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy	9
Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing	9
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year p	9
Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement	9
Is there a gender effect in polycythemia vera?	9
Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients	9
Long non-coding RNAs and MYC association in hematological malignancies	9
Possible nosocomial transmission of virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation	9
Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow	9
Gene mutation profile in patients with acquired pure red cell aplasia	9
Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis	9
Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation	9
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patien	9
Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era	9
Influence of UGT1A1 promoter polymorphism, α-thalassemia and βs haplotype in bilirubin levels and cholelithiasis in a large sickle cell anemia cohort	9
Ruxolitinib treatment improves muscle mass in patients with myelofibrosis	9
Thalassemia in the emergency department: special considerations for a rare disease	9
Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience	9
The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease	9
Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review	9
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study	9
ADAMTS-13–VWF axis in sickle cell disease patients	9
The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation	9
Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients	8
Tacrolimus ameliorates thrombocytopenia in an ITP mouse model	8
Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center	8
CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia	8
Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia – a nested case-control study	8
Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005–2016	8
Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase	8
Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis	8
Genetic research and clinical analysis of deletional Chinese Gγ+(Aγδβ)0 -thalassemia and Southeast Asian HPFH in South China	8
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study	8
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac	8
First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis	8
Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies	8
Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program	8
Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy	8
Prospective analysis of BKV hemorrhagic cystitis in children and adolescents undergoing hematopoietic cell transplantation	8
Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma	8
Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis	8
Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants	8
Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera	8
Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine	8
A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reac	8
Adult aplastic anemia in Thailand: incidence and treatment outcome from a prospective nationwide population-based study	8
Phenotypical and functional abnormalities of circulating neutrophils in patients with β-thalassemia	8
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients	8
Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA	7
The anemia-independent impact of myelodysplastic syndromes on health-related quality of life	7
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns	7
Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India	7
Profiling of bacterial bloodstream infections in hematological and oncological patients based on a comparative survival analysis	7
Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis	7
Temporal trends and outcome of splenectomy in adults with immune thrombocytopenia in the USA	7
Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes	7
Liver damage and sickle cell disease: genotype relationship	7
Prevalence of anaemia and associated risk factors amongst The Malaysian Cohort participants	7
Successful treatment of hairy cell leukemia variant with obinutuzumab	7
Characteristics of Sweet syndrome in patients with or without malignancy	7
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients	7
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients	7
Long-term outcome after allogeneic stem cell transplantation in multiple myeloma	7
Acquired amegakaryocytic thrombocytopenic purpura possibly induced by anti-PD-1 antibody	7
Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm	7
Peripherally inserted central venous catheters decrease central line-associated bloodstream infections and change microbiological epidemiology in adult hematology unit: a propensity score-adjusted ana	7
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients	7
Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation	7